Table 3.
Results of univariable and multivariable regression models relating sociodemographic, clinical, and molecular variables to fatigue among patients with AML.
| Univariable Analysis | Multivariable Analysis | |||||
|---|---|---|---|---|---|---|
| Estimate | 95% CI | p | Estimate | 95% CI | p | |
| Sociodemographic variables | ||||||
| Female sex | −2.11 | 3.70, −0.53 | 0.009 | −2.30 | −4.01, −0.59 | 0.009 |
| Age | −0.03 | −0.11, 0.05 | 0.437 | NA | NA | NA |
| Clinical variables | ||||||
| WHO performance status ≥1 | −3.15 | −4.79, −1.52 | <0.001 | −2.55 | −4.30, −0.81 | 0.004 |
| ≥1 comorbidity | −1.26 | −3.47, 0.95 | 0.262 | NA | NA | NA |
| Hb level, g/dL | 0.56 | 0.12, 0.99 | 0.013 | 0.06 | −0.43, 0.54 | 0.815 |
| WBC count, x109/L | −0.35 | −0.51, −0.19 | <0.001 | −0.15 | −0.34, 0.04 | 0.125 |
| Blast cells, % | −0.05 | −0.08, −0.02 | <0.001 | −0.02 | −0.05, 0.02 | 0.314 |
| Platelet count, x109/L | 0.18 | 0.08, 0.28 | 0.001 | 0.22 | 0.08, 0.37 | 0.002 |
| Molecular variables | ||||||
| FLT3-ITD | −2.08 | −3.90, −0.26 | 0.025 | −0.05 | −2.05, 1.95 | 0.961 |
| RUNX1-RUNX1T1 | 0.20 | −3.27, 3.68 | 0.908 | NA | NA | NA |
| CBFβ-MYH11 | −0.14 | −3.21, 2.93 | 0.928 | NA | NA | NA |
| NMP1 | −0.17 | −1.83, 1.49 | 0.839 | NA | NA | NA |
Only significant univariable predictors of fatigue were included in the multivariable analysis.
Abbreviations: WHO, World Health Organization; Hb, hemoglobin; WBC, white blood cell.